ANIX (Anixa Biosciences) EPS (Basic): $-0.31 (TTM As of Apr. 2026)

What is Anixa Biosciences EPS (Basic)?

Anixa Biosciences ANIX -0.76% 27 EPS (Basic) is $-0.31 as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Anixa Biosciences's basic earnings per share (Basic EPS) for the three months ended in Apr. 2026 was $-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.31.

Anixa Biosciences's EPS (Diluted) for the three months ended in Apr. 2026 was $-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.31.

Anixa Biosciences's EPS without NRI for the three months ended in Apr. 2026 was $-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was -0.31.

During the past 3 years, the average EPS without NRI Growth Rate was 8.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Anixa Biosciences's highest 3-Year average EPS without NRI Growth Rate was 43.20% per year. The lowest was -73.10% per year. And the median was 4.60% per year.

Anixa Biosciences (NAS:ANIX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Anixa Biosciences EPS (Basic) Related Terms

Anixa Biosciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences EPS (Basic) Chart

Anixa Biosciences Annual Data

Trend

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Oct25

EPS (Basic)

Get a 7-Day Free Trial

-0.45

-0.32

-0.39

-0.34

Anixa Biosciences Quarterly Data
	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26	Apr26
EPS (Basic)	Get a 7-Day Free Trial															-0.09	-0.07	-0.09	-0.08	-0.07

27GF Score

Anixa Biosciences Inc ANIX

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Anixa Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Anixa Biosciences's Basic EPS for the fiscal year that ended in Oct. 2025 is calculated as

Basic EPS (A: Oct. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-10.927	-	0)	/	32.454
	=	-0.34

Anixa Biosciences's Basic EPS for the quarter that ended in Apr. 2026 is calculated as

Basic EPS (Q: Apr. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.516	-	0)	/	33.593
	=	-0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.31 mean?

Anixa Biosciences (ANIX) has a EPS (Basic) of $-0.31 as of Apr. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anixa Biosciences and its competitors.

Is Anixa Biosciences' EPS (Basic) too high?

Anixa Biosciences' current EPS (Basic) is $-0.31. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.

How does Anixa Biosciences' EPS (Basic) compare to PYPD and LONA?

Anixa Biosciences' EPS (Basic) of $-0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current EPS (Basic) is $-0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Anixa Biosciences stock overvalued right now?

Anixa Biosciences (ANIX) has a current EPS (Basic) of $-0.31. The current EPS (Basic) is $-0.31. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current EPS (Basic) is $-0.31 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies PYPD LONA SGMO OKYO AARD ICCC TELO NRXS PTHS CUE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges CY71:Germany

Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website https://www.anixa.com

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

27GF Score

Get the complete analysis for ANIX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62

Price

View ANIX Analysis

See EPS (Basic) data for all stocks →